search
Back to results

IV Gallium Study for Patients With Cystic Fibrosis Who Have NTM (ABATE Study) (ABATE)

Primary Purpose

Nontuberculous Mycobacterium Infection

Status
Recruiting
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
Gallium nitrate
Sponsored by
Chris Goss
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Nontuberculous Mycobacterium Infection focused on measuring Cystic Fibrosis, Gallium Nitrate, IV Gallium, Nontuberculous mycobacterium, NTM, Mycobacterium abscessus, mycobacterium avium

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Written informed consent obtained from subject or subject's legal representative
  2. Be willing and able to adhere to the study visit schedule and other protocol requirements
  3. All sexes ≥ 18 years of age at Visit 1
  4. Documentation of a CF diagnosis as evidenced by one or more clinical features consistent with the CF phenotype.
  5. Documentation of persistently positive NTM culture results that are positive for the same species or sub-species (either M. avium complex, M. abscessus complex, or both M. avium and M. abscessus). Persistently positive cultures are those which meet ONE of the following criteria, after first ignoring any negative culture results that occur within 7 days of a positive culture:

    1. The two most recent NTM culture results from sputum or BAL taken at least 28 days apart are positive.

      OR

    2. At least one NTM culture result in the previous 4 months from sputum or BAL is positive. If there are four or more cultures in the last 12-months at least 3 out of the 4 most recent cultures must be positive for NTM. If there are three or fewer cultures in the past 12 months, then at least 2 of the 3 most recent cultures must be positive for NTM even if some of those cultures are more than 12 months ago.
  6. Current NTM species or subspecies has never been treated or previous treatment was associated with clearance of NTM and completed > 2 years prior to Day 1
  7. FEV1 ≥ 25 % of predicted value at Screening
  8. Able to expectorate sputum
  9. Clinically stable with no significant changes in health status within 7 days prior to Day 1
  10. Enrolled in the CFF Patient Registry (CFF PR)
  11. Willing to discontinue chronic azithromycin use for the duration of the study

Exclusion Criteria:

  1. Any of the following abnormal lab values at screening:

    • Hemoglobin <10g/dL
    • Platelets <100,000/mm3
    • Absolute neutrophil count < 1500/mm3
    • Aspartate transaminase (AST), alanine transaminase (ALT), gamma-glutamyl transferase (GGT), or alkaline phosphatase (ALP) ≥3 x upper limit of normal
    • Serum creatinine > 2.0 mg/dl and ≥1.5 x upper limit of normal
    • Ionized calcium ≤ lower limit of normal (only performed if total calcium is ≤ lower limit of normal)
  2. History of solid organ or hematological transplantation
  3. Use of bisphosphonates within 7 days prior to Day 1
  4. Known sensitivity to gallium
  5. Use of any investigational drug and/or participated in any interventional clinical trial within 28 days prior to Day 1
  6. In the opinion of the Investigator, features of active NTM disease are present (e.g., clinical worsening is likely due to NTM disease despite definitive treatment of co-pathogens and/or acute exacerbations)
  7. Undergoing treatment for NTM disease or anticipate beginning treatment within 3 months
  8. Current diagnosis of osteoporosis
  9. For people of childbearing potential:

    • Positive pregnancy test at Visit 1 or
    • Lactating or
    • Unwilling to practice a medically acceptable form of contraception (acceptable forms of contraception: abstinence, hormonal birth control, intrauterine device, or barrier method plus a spermicidal agent), unless surgically sterilized or postmenopausal during the study
  10. For people able to father a child: unwilling to use adequate contraception (as determined by the investigator) during the study
  11. Has any other condition that, in the opinion of the Site Investigator/designee, would preclude informed consent or assent, make study participation unsafe, complicate interpretation of study outcome data, or otherwise interfere with achieving the study objectives
  12. New initiation of chronic therapy (e.g., CFTR modulators, ibuprofen, azithromycin, inhaled tobramycin, Cayston, etc.) within 28 days prior to Visit 1 (Day 1)
  13. Use of azithromycin within 14 days prior to the screening visit.

Sites / Locations

  • University of Alabama at BirminghamRecruiting
  • National Jewish HealthRecruiting
  • Johns Hopkins UniversityRecruiting
  • Nationwide Children's HospitalRecruiting
  • University of Pittsburgh Medical CenterRecruiting
  • Medical University of South CarolinaRecruiting
  • University of Texas SouthwesternRecruiting
  • University of Vermont Medical CenterRecruiting
  • University of Washington Medical CenterRecruiting

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Infusion of IV Gallium

Arm Description

Gallium nitrate will be infused continuously over 5 days at 200 mg/m2/day. Study drug will be administered via a peripheral IV catheter, a peripherally inserted central catheter (PICC) line, midline catheter, or a chronic indwelling vascular access device using an ambulatory infusion pump infused over 24 hours for 5 sequential days for each cycle. There is a maximum of 2 cycles.

Outcomes

Primary Outcome Measures

Adverse Events of Special Interest
Proportion of patients experiencing one or more Adverse Events of Special Interest (AESI). AESIs include the occurrence of either (1) a serious adverse event (SAE) of grade 3 or higher including hospitalizations or (2) study drug discontinuation because of an AE.

Secondary Outcome Measures

Clinically significant abnormal laboratory measures. (safety)
Proportion of patients experiencing clinically significant abnormal laboratory measures. Clinically significant abnormal laboratory measures are identified by the site investigator.
NTM clearance (efficacy)
Proportion of subjects who were NTM culture positive at baseline and have at least 2 sequential negative NTM cultures between visits 2 (Day 6) and 7 (Day 111). Those negative cultures must be at least 2 weeks apart.

Full Information

First Posted
March 1, 2020
Last Updated
January 10, 2023
Sponsor
Chris Goss
Collaborators
Cystic Fibrosis Foundation
search

1. Study Identification

Unique Protocol Identification Number
NCT04294043
Brief Title
IV Gallium Study for Patients With Cystic Fibrosis Who Have NTM (ABATE Study)
Acronym
ABATE
Official Title
A Phase 1b, Multi-center Study of Intravenous (IV) Gallium Nitrate in Patients With Cystic Fibrosis (CF) Who Are Colonized With Nontuberculous Mycobacteria (NTM) (The ABATE Study)
Study Type
Interventional

2. Study Status

Record Verification Date
January 2023
Overall Recruitment Status
Recruiting
Study Start Date
June 17, 2021 (Actual)
Primary Completion Date
September 30, 2023 (Anticipated)
Study Completion Date
June 30, 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Chris Goss
Collaborators
Cystic Fibrosis Foundation

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The purpose of this study is to assess the safety and tolerability of two 5-day infusion cycles of IV gallium in adult patients with CF who are infected with NTM. Funding Source - FDA OOPD
Detailed Description
This is a prospective, multicenter open-label study in adults with CF who are colonized with M. avium complex and/or M. abscessus complex. Subjects will receive two 5-day infusion cycles of IV gallium. The study will evaluate the safety and antimycobacterial effect of two 5-day infusions of IV gallium.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Nontuberculous Mycobacterium Infection
Keywords
Cystic Fibrosis, Gallium Nitrate, IV Gallium, Nontuberculous mycobacterium, NTM, Mycobacterium abscessus, mycobacterium avium

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
40 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Infusion of IV Gallium
Arm Type
Experimental
Arm Description
Gallium nitrate will be infused continuously over 5 days at 200 mg/m2/day. Study drug will be administered via a peripheral IV catheter, a peripherally inserted central catheter (PICC) line, midline catheter, or a chronic indwelling vascular access device using an ambulatory infusion pump infused over 24 hours for 5 sequential days for each cycle. There is a maximum of 2 cycles.
Intervention Type
Drug
Intervention Name(s)
Gallium nitrate
Other Intervention Name(s)
Ga, GaN3O9, IV gallium, ganite
Intervention Description
Study subjects will receive an infusion of gallium nitrate.
Primary Outcome Measure Information:
Title
Adverse Events of Special Interest
Description
Proportion of patients experiencing one or more Adverse Events of Special Interest (AESI). AESIs include the occurrence of either (1) a serious adverse event (SAE) of grade 3 or higher including hospitalizations or (2) study drug discontinuation because of an AE.
Time Frame
Baseline to Day 57
Secondary Outcome Measure Information:
Title
Clinically significant abnormal laboratory measures. (safety)
Description
Proportion of patients experiencing clinically significant abnormal laboratory measures. Clinically significant abnormal laboratory measures are identified by the site investigator.
Time Frame
Baseline to Day 57
Title
NTM clearance (efficacy)
Description
Proportion of subjects who were NTM culture positive at baseline and have at least 2 sequential negative NTM cultures between visits 2 (Day 6) and 7 (Day 111). Those negative cultures must be at least 2 weeks apart.
Time Frame
Day 6 to Day 111

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Written informed consent obtained from subject or subject's legal representative Be willing and able to adhere to the study visit schedule and other protocol requirements All sexes ≥ 18 years of age at Visit 1 Documentation of a CF diagnosis as evidenced by one or more clinical features consistent with the CF phenotype. Documentation of persistently positive NTM culture results that are positive for the same species or sub-species (either M. avium complex, M. abscessus complex, or both M. avium and M. abscessus). Persistently positive cultures are those which meet ONE of the following criteria, after first ignoring any negative culture results that occur within 7 days of a positive culture: The two most recent NTM culture results from sputum or BAL taken at least 28 days apart are positive. OR At least one NTM culture result in the previous 4 months from sputum or BAL is positive. If there are four or more cultures in the last 12-months at least 3 out of the 4 most recent cultures must be positive for NTM. If there are three or fewer cultures in the past 12 months, then at least 2 of the 3 most recent cultures must be positive for NTM even if some of those cultures are more than 12 months ago. Current NTM species or subspecies has never been treated or previous treatment was associated with clearance of NTM and completed > 2 years prior to Day 1 FEV1 ≥ 25 % of predicted value at Screening Able to expectorate sputum Clinically stable with no significant changes in health status within 7 days prior to Day 1 Enrolled in the CFF Patient Registry (CFF PR) Willing to discontinue chronic azithromycin use for the duration of the study Exclusion Criteria: Any of the following abnormal lab values at screening: Hemoglobin <10g/dL Platelets <100,000/mm3 Absolute neutrophil count < 1500/mm3 Aspartate transaminase (AST), alanine transaminase (ALT), gamma-glutamyl transferase (GGT), or alkaline phosphatase (ALP) ≥3 x upper limit of normal Serum creatinine > 2.0 mg/dl and ≥1.5 x upper limit of normal Ionized calcium ≤ lower limit of normal (only performed if total calcium is ≤ lower limit of normal) History of solid organ or hematological transplantation Use of bisphosphonates within 7 days prior to Day 1 Known sensitivity to gallium Use of any investigational drug and/or participated in any interventional clinical trial within 28 days prior to Day 1 In the opinion of the Investigator, features of active NTM disease are present (e.g., clinical worsening is likely due to NTM disease despite definitive treatment of co-pathogens and/or acute exacerbations) Undergoing treatment for NTM disease or anticipate beginning treatment within 3 months Current diagnosis of osteoporosis For people of childbearing potential: Positive pregnancy test at Visit 1 or Lactating or Unwilling to practice a medically acceptable form of contraception (acceptable forms of contraception: abstinence, hormonal birth control, intrauterine device, or barrier method plus a spermicidal agent), unless surgically sterilized or postmenopausal during the study For people able to father a child: unwilling to use adequate contraception (as determined by the investigator) during the study Has any other condition that, in the opinion of the Site Investigator/designee, would preclude informed consent or assent, make study participation unsafe, complicate interpretation of study outcome data, or otherwise interfere with achieving the study objectives New initiation of chronic therapy (e.g., CFTR modulators, ibuprofen, azithromycin, inhaled tobramycin, Cayston, etc.) within 28 days prior to Visit 1 (Day 1) Use of azithromycin within 14 days prior to the screening visit.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Natallia Cameron
Phone
206-884-7550
Email
Natallia.Cameron@seattlechildrens.org
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Christopher H. Goss, MD, MSc
Organizational Affiliation
University of Washington, Seattle Children's Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Alabama at Birmingham
City
Birmingham
State/Province
Alabama
ZIP/Postal Code
35294
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Justin Wade
Email
jdwade@uabmc.edu
Facility Name
National Jewish Health
City
Denver
State/Province
Colorado
ZIP/Postal Code
80206
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Alix Wilson
Email
wilsona@njhealth.org
Facility Name
Johns Hopkins University
City
Baltimore
State/Province
Maryland
ZIP/Postal Code
21205
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Britany Zeglin
Email
bzeglin1@jhmi.edu
Facility Name
Nationwide Children's Hospital
City
Columbus
State/Province
Ohio
ZIP/Postal Code
43205
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Diana Gilmore
Email
diana.gilmore@nationwidechildrens.org
Facility Name
University of Pittsburgh Medical Center
City
Pittsburgh
State/Province
Pennsylvania
ZIP/Postal Code
15224
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Elizabeth Hartigan
Email
elizabeth.hartigan@chp.edu
Facility Name
Medical University of South Carolina
City
Charleston
State/Province
South Carolina
ZIP/Postal Code
29425
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ashley Warden
Email
jonesash@musc.edu
Facility Name
University of Texas Southwestern
City
Dallas
State/Province
Texas
ZIP/Postal Code
75390
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ashley Keller
Email
Ashley.Keller@UTSouthwestern.edu
Facility Name
University of Vermont Medical Center
City
Burlington
State/Province
Vermont
ZIP/Postal Code
05401
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Julie Sweet
Email
julie.sweet@uvmhealth.org
Facility Name
University of Washington Medical Center
City
Seattle
State/Province
Washington
ZIP/Postal Code
98195
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Teresa Gambol
Email
TGambol@medicine.washington.edu

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

IV Gallium Study for Patients With Cystic Fibrosis Who Have NTM (ABATE Study)

We'll reach out to this number within 24 hrs